Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Novartis AG's Enterprise Value is $211,336 Mil.
Novartis AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $10,312 Mil. Therefore, Novartis AG's EV-to-EBIT ratio for today is 20.49.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Novartis AG's Enterprise Value is $211,336 Mil.
Novartis AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $18,832 Mil. Therefore, Novartis AG's EV-to-EBITDA ratio for today is 11.22.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Novartis AG's Enterprise Value is $211,336 Mil.
Novartis AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $51,012 Mil. Therefore, Novartis AG's EV-to-Revenue ratio for today is 4.14.
Novartis AG Enterprise Value Historical Data
The historical data trend for Novartis AG's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Novartis AG's Enterprise Value
For the Drug Manufacturers - General subindustry, Novartis AG's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novartis AG's Enterprise Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Novartis AG's Enterprise Value falls into.
Novartis AG Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Novartis AG's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novartis AG (NYSE:NVS) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Novartis AG's current Enterprise Value is $211,336 Mil.
Novartis AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $10,312 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Novartis AG's current Enterprise Value is $211,336 Mil.
Novartis AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $18,832 Mil.
Novartis AG's current Enterprise Value is $211,336 Mil.
Novartis AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $51,012 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novartis AG Enterprise Value Related Terms
Thank you for viewing the detailed overview of Novartis AG's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NVS has been successfully added to your 